To evaluate the Safety and efficacy of Unani formulation Sharbat-e-Faulad in the treatment of Anaemia.

Validation of Unani Pharmacopoeial formulation Sharbat-e-Faulad in Soo ul Qiniya (Anaemia) patients.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/10/004068

Enrollment

300

Registered

2013-10-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified Health Condition 2: null- Soo ul Qiniya (Anaemia) patients.

Interventions

Intervention1: Sharbat-e-Faulad: DOSE: 12 ML ORALLY TWICE A DAY FOR 12 WEEKS Intervention2: Sharbat-e-Faulad: DOSE: 12 ML TWICE A DAY Control Intervention1: NIL: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1. Whitish or yellowish Complexion of face and skin 2. Pedal edema. 3. Hb% in the range of 8-12 mg % in males and 8-10 mg % in females

Exclusion criteria

Exclusion criteria: 1. Patients with Hemoglobin less than 8 mg % 2. Patients with history of Acute Blood loss. 3. Patients with chronic diseases requiring long term treatment. 4. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptomsTimepoint: 12 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDR ABDUL HANNAN

Central Council for Research in Unani Medicine (CCRUM

ccrum605@gmail.com011-28521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026